Revolution Medicines to Participate in Upcoming Investor Conferences
March 09, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines Reports Fourth Quarter and Year-End 2020 Financial Results and Update on Corporate Progress
March 02, 2021 16:05 ET
|
Revolution Medicines, Inc.
Advanced and Expanded Portfolio of RAS(ON) Inhibitors; Two Assets Entered IND-Enabling Development Continued Progress in Development of RAS Companion Inhibitors to Support Targeted Combination...
Revolution Medicines to Participate in Digital RAS-Targeted Drug Discovery Summit and Upcoming Investor Conferences
February 18, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
February 08, 2021 16:01 ET
|
Revolution Medicines, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $300 Million REDWOOD CITY, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD) today announced the...
Revolution Medicines Announces Pricing of Upsized $260.9 Million Public Offering of Common Stock
February 03, 2021 23:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced the pricing of its underwritten public offering of 5,797,101 shares of common stock...
Revolution Medicines Announces Proposed Public Offering of Common Stock
February 01, 2021 16:01 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD) today announced that it has commenced an underwritten public offering of 4,000,000 shares of common...
Revolution Medicines to Provide R&D Pipeline Update, Including Progress of RAS(ON) Inhibitor Programs, During Presentation at 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...
Revolution Medicines Reports Third Quarter 2020 Financial Results and Update on Corporate Progress
November 12, 2020 07:30 ET
|
Revolution Medicines, Inc.
Recommended Phase 2 Dose and Schedule Selected for Further Evaluation of RMC-4630 as Monotherapy and RMC-4630 plus Cobimetinib Combination First-in-Class RAS(ON) Inhibitor Programs for Five Targets...
Revolution Medicines Reports Progress and Expansion of Combination Strategy with RMC-4630 as Therapeutic Backbone for RAS-Addicted Cancers
October 24, 2020 09:45 ET
|
Revolution Medicines, Inc.
Plenary Presentation at EORTC-NCI-AACR 32nd Symposium on Molecular Targets and Cancer Therapeutics Describes Encouraging Tolerability and Exposure Profiles for RMC-4630 Combined with Cobimetinib and...
Revolution Medicines to Present Interim Data at ENA 2020 from Phase 1b/2 Clinical Trial Combining RMC-4630 with Cobimetinib for RAS-Addicted Solid Tumors
October 12, 2020 07:30 ET
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage precision oncology company developing targeted therapies to inhibit frontier...